Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

07/28/2021 | 05:53am EDT

Pursuant to the Codes on Takeovers and Mergers and Share Repurchases ('Takeovers Codes'), a copy of each document to be displayed under Note 1 to Rule 8 of the Takeovers Codes must be provided by the issuer of the offer document or offeree board circular, as appropriate, to Securities and Futures Commission ('SFC') for display on the SFC's website. To access these documents on display, you can either click this link https://www.sfc.hk/dod/jsp/EN/DoDmain.jsp or click the View Documents on Displaybutton next to the subject title of the offer document or offeree board circular.

Some of the files are prepared in the portable document format and viewing them requires Adobe(R) Reader(R) which can be downloaded free of charge.

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 09:52:03 UTC.


ę Publicnow 2021
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
09/22SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Raises Nearly $186 Million from Sale of Renmi..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Wins US FDA Nod to Start Clinical Trial of Ex..
MT
09/21SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - on completion of the issuance of ..
PU
09/10SHANGHAI FOSUN PHARMACEUTICAL : Proposed adoption of rsu scheme by a subsidiary (h ..
PU
09/02SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
09/01Helped by TSMC and Foxconn, BioNTech vaccines finally reach Taiwan
RE
09/01SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Secures Another $100 Million For COVID-19 Vac..
MT
08/25REFILE-Taiwan says BioNTech shots available earlier than expected
RE
08/25REFILE-Taiwan to get BioNTech shots early as China delays approval-source
RE
08/24SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces 2021 Interim Results Innovative Pro..
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 37 550 M 5 814 M 5 814 M
Net income 2021 4 674 M 724 M 724 M
Net Debt 2021 17 898 M 2 771 M 2 771 M
P/E ratio 2021 30,8x
Yield 2021 0,90%
Capitalization 135 B 20 830 M 20 830 M
EV / Sales 2021 4,06x
EV / Sales 2022 3,46x
Nbr of Employees 34 375
Free-Float 57,5%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 57,01 CNY
Average target price 68,40 CNY
Spread / Average Target 20,0%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman